Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
Status:
Completed
Trial end date:
2015-01-08
Target enrollment:
Participant gender:
Summary
This study will investigate the relative bioavailability of two candidate tablet formulations
of 16 milligram (mg) Candesartan cilexetil (GW615775) compared with the reference product
ATACAND™ containing 16 mg Candesartan cilexetil in healthy human subjects. This is an
open-label, randomized, single dose, three-way crossover, six sequence study enrolling 18
healthy human subjects to ensure at least 14 subjects complete the study as planned. Each
subject enrolled will participate in all three treatment periods and will be assigned to one
of the six treatment sequences, in accordance with the randomization schedule. The treatment
periods will be separated by a washout period of at least 7 days and no more than 14 days
between dosing occasions. A follow up visit will be conducted 14-21 days post last dosing.
ATACAND is a registered trademark of the AstraZeneca group of companies.